Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for Tarsus Pharmaceuticals (TARS) over the last 4 years, with Sep 2025 value amounting to $10.1 million.

  • Tarsus Pharmaceuticals' Other Non-Current Liabilities rose 718.39% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 718.39%. This contributed to the annual value of $1.7 million for FY2023, which is 1648.00% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Other Non-Current Liabilities stood at $10.1 million, which was up 718.39% from $1.2 million recorded in Q3 2024.
  • In the past 5 years, Tarsus Pharmaceuticals' Other Non-Current Liabilities registered a high of $10.1 million during Q3 2025, and its lowest value of $40,000 during Q1 2023.
  • In the last 3 years, Tarsus Pharmaceuticals' Other Non-Current Liabilities had a median value of $1.7 million in 2023 and averaged $2.5 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Other Non-Current Liabilities tumbled by 91.94% in 2023 and then surged by 3,915.00% in 2024.
  • Tarsus Pharmaceuticals' Other Non-Current Liabilities (Quarterly) stood at $699,000 in 2021, then tumbled by 85.69% to $100,000 in 2022, then skyrocketed by 1,648.00% to $1.7 million in 2023, then declined by 27.53% to $1.2 million in 2024, then spiked by 718.39% to $10.1 million in 2025.
  • Its Other Non-Current Liabilities stands at $10.1 million for Q3 2025, versus $1.2 million for Q3 2024 and $1.4 million for Q2 2024.